This highly curated knowledge base contains detailed descriptions of 88 non-animal models being used for immunogenicity in ATMP, mostly employed to test cell therapy products. T cells from peripheral blood of healthy donors cultured in 2D conditions represent the main model applied to test immunogenicity. Very few studies were reporting advanced models , such as embedded cells in extracellular matrix, organoids and spheroids.
European Commission, Joint Research Centre (2026): EURL ECVAM Review of non-animal models in biomedical research - Immunogenicity Testing of Advanced Therapy Medicinal Products (ATMP). [Dataset] doi: 10.2905/JRC.BMFVP68 PID: http://data.europa.eu/89h/c1c15110-2338-422e-a228-d3f8e19262c3
advanced therapy medicinal products (ATMP)immunogenicitynon-animal
Review of advanced non-animal models for Immunogenicity Testing of Advanced Therapy Medicinal Products (ATMP)-The JRC’s EU Reference Laboratory for alternatives to animal testing (EURL ECVAM) conducted a study to systematically review the state-of-the art of advanced non-animal models used in immunogenicity testing for ATMPs. The majority of the 88 models that were identified, focused on in vitro (with a limited amount of in silico) techniques and mostly included the investigation of cell therapy products. Furthermore, most of the identified methods were of low throughput and low content and based on classical 2D primary cell cultures. This review highlights an urgent need for the development and acceptance of more sophisticated and innovative non-animal approaches in this e field of immunogenicity testing for ATMPs, which will pave the way for the broader use of ATMPs in the clinic.
| From date | To date |
|---|---|
| 2014-01-01 | 2019-03-31 |
